Pure Global
NCT06395844

Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer: A Single-arm, Single-center, Exploratory Clinical Study
Anhui Provincial Cancer Hospital·Phase 1/2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ovarian Cancer
Drug/Device/Intervention
METR-NK cell(Metabolic Remodeling Nature Killer Cells)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Anhui Provincial Cancer Hospital
Location
Hefei, China
Timeline & enrollment
Phase
Phase 1/2
Start date
May 01, 2024
End date
Dec 31, 2026
Enrollment
28 participants
Primary outcome

R0 resection rate

Summary

The goal of this type of clinical trial study is to evaluate the safety and efficacy of
 metabolic remodeling nature killer cells as neoadjuvant therapy in newly diagnosed patients
 with advanced ovarian cancer

ICD-10 classifications
Malignant neoplasm of ovarySecondary malignant neoplasm of ovaryBenign neoplasm of ovaryOvarian pregnancyOvarian dysfunction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06395844
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06395844 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Anhui Provincial Cancer Hospital and is currently Recruiting. The study focuses on Ovarian Cancer. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.